Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (451-460 of 568) with videos related to

Pageof 57
Sort By:
Cancers|February 11, 2023
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry StudyIvan Guerra, Luis Bujanda, Miriam Mañosa, et al.
European Journal of Clinical Investigation|July 9, 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME studyFerdinando D'Amico, Luca Massimino, Giulia Palmieri, et al.
Alimentary Pharmacology & Therapeutics|March 6, 2024
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)María José García, Sabino Riestra, Aurelien Amiot, et al.
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 29, 2026
Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumabPatricia de Castro-Martínez, Luis G Guijarro, Jorge Monserrat, et al.
Gastroenterology|January 6, 2015
Identification of risk loci for Crohn's disease phenotypes using a genome-wide association studyArnald Alonso, Eugeni Domènech, Antonio Julià, et al.
Journal of Crohn'S & Colitis|July 28, 2018
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel DiseaseCarlos Taxonera, Ángel Ponferrada, Sabino Riestra, et al.
Cancers|July 2, 2021
Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor LesionsAntonio Gómez, Miguel L Pato, Luis Bujanda, et al.
Biomedicines|March 25, 2022
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease SeverityLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
Pageof 57

Showing results (451-460 of 568) with videos related to

Sort By:
Pageof 57
Cancers|February 11, 2023
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry StudyIvan Guerra, Luis Bujanda, Miriam Mañosa, et al.
European Journal of Clinical Investigation|July 9, 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME studyFerdinando D'Amico, Luca Massimino, Giulia Palmieri, et al.
Alimentary Pharmacology & Therapeutics|March 6, 2024
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)María José García, Sabino Riestra, Aurelien Amiot, et al.
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 29, 2026
Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumabPatricia de Castro-Martínez, Luis G Guijarro, Jorge Monserrat, et al.
Gastroenterology|January 6, 2015
Identification of risk loci for Crohn's disease phenotypes using a genome-wide association studyArnald Alonso, Eugeni Domènech, Antonio Julià, et al.
Journal of Crohn'S & Colitis|July 28, 2018
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel DiseaseCarlos Taxonera, Ángel Ponferrada, Sabino Riestra, et al.
Cancers|July 2, 2021
Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor LesionsAntonio Gómez, Miguel L Pato, Luis Bujanda, et al.
Biomedicines|March 25, 2022
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease SeverityLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
Pageof 57